Thursday, May 3, 2018

CTC Status May Help Predict Benefit Of Radiotherapy In Individuals With Early-Stage Breast Cancer, Research Indicates.

MedPage Today (5/3, Jenkins) reports that research indicates “circulating tumor cell (CTC) status may be an important clinical marker for predicting the benefit of radiotherapy (RT) in patients with early-stage breast cancer.” After analyzing “more than 3,000 patients who underwent breast-conserving surgery (BCS) from the National Cancer Database (NCDB) and phase III SUCCESS trial,” investigators found “that RT was associated with longer overall survival in those with at least one CTC.” The link “was not seen among patients without CTCs.” The findings were published in JAMA Oncology.

Author: Nicole Hardy

Categories: 2018, May, News, Screening and MammographyNumber of views: 2031


Theme picker